Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Oppenheimer Stick to Their Hold Rating for Epizyme

Published 07/07/2020, 06:45 AM
Updated 07/07/2020, 06:45 AM


Oppenheimer analyst Leland Gershell reiterated a Hold rating on Epizyme (NASDAQ:EPZM) on Tuesday, setting a price target of $17, which is approximately 7.46% above the present share price of $15.82.

Gershell expects Epizyme to post earnings per share (EPS) of -$0.51 for the third quarter of 2020.

The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Epizyme, with an average price target of $28.57.
The analysts price targets range from a high of $36 to a low of $16.

In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $1.35 million and a net profit of -$51.35 million. The company's market cap is $1.6 billion.

According to TipRanks.com, Oppenheimer analyst Leland Gershell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.0% and a 53.22% success rate.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.